Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May;25(5):679-701.
doi: 10.1007/s11864-024-01203-6. Epub 2024 Apr 27.

Precision Cardio-oncology: Update on Omics-Based Diagnostic Methods

Ziyu Kuang #  1   2 , Miao Kong #  1 , Ningzhe Yan #  1   2 , Xinyi Ma  1 , Min Wu  3 , Jie Li  4
Affiliations
Review

Precision Cardio-oncology: Update on Omics-Based Diagnostic Methods

Ziyu Kuang et al. Curr Treat Options Oncol. 2024 May.

Abstract

Cardio-oncology is an emerging interdisciplinary field dedicated to the early detection and treatment of adverse cardiovascular events associated with anticancer treatment, and current clinical management of anticancer-treatment-related cardiovascular toxicity (CTR-CVT) remains limited by a lack of detailed phenotypic data. However, the promise of diagnosing CTR-CVT using deep phenotyping has emerged with the development of precision medicine, particularly the use of omics-based methodologies to discover sensitive biomarkers of the disease. In the future, combining information produced by a variety of omics methodologies could expand the clinical practice of cardio-oncology. In this review, we demonstrate how omics approaches can improve our comprehension of CTR-CVT deep phenotyping, discuss the positive and negative aspects of available omics approaches for CTR-CVT diagnosis, and outline how to integrate multiple sets of omics data into individualized monitoring and treatment. This will offer a reliable technical route for lowering cardiovascular morbidity and mortality in cancer patients and survivors.

Keywords: Cardio-oncology; Cardiotoxicity; Omics; Precision medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Omics classification for the diagnosis of CTR-CVD (Created with BioRender.com).
See this image and copyright information in PMC

References

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Brenner H, Schrotz-King P, Holleczek B, Katalinic A, Hoffmeister M. Declining bowel cancer incidence and mortality in Germany. Dtsch Arztebl Int. 2016;113:101–106. doi: 10.3238/arztebl.2016.0101. - DOI - PMC - PubMed
    1. Wakabayashi G, Lee Y-C, Luh F, Kuo C-N, Chang W-C, Yen Y. Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. J Biomed Sci. 2019;26:96. doi: 10.1186/s12929-019-0588-8. - DOI - PMC - PubMed
    1. Zhou S, Cirne F, Chow J, Zereshkian A, Bordeleau L, Dhesy-Thind S, Ellis PM, Mukherjee SD, Aghel N, Leong DP. Three-year outcomes following permissive cardiotoxicity in patients on trastuzumab. Oncologist. 2023;28(9):e712–e722. doi: 10.1093/oncolo/oyad086. - DOI - PMC - PubMed
    1. Yan T, Yu L, Zhang J, Chen Y, Fu Y, Tang J, Liao D. Achilles' Heel of currently approved immune checkpoint inhibitors: immune related adverse events. Front Immunol. 2024;12(15):1292122. doi: 10.3389/fimmu.2024.1292122.PMID:38410506;PMCID:PMC10895024. - DOI - PMC - PubMed
    1. Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17:474–502. doi: 10.1038/s41569-020-0348-1. - DOI - PMC - PubMed

Publication types

MeSH terms